BR0011520A - Polìmeros aniÈnicos usados como ligantes de toxinas e agentes antibacterianos - Google Patents

Polìmeros aniÈnicos usados como ligantes de toxinas e agentes antibacterianos

Info

Publication number
BR0011520A
BR0011520A BR0011520-7A BR0011520A BR0011520A BR 0011520 A BR0011520 A BR 0011520A BR 0011520 A BR0011520 A BR 0011520A BR 0011520 A BR0011520 A BR 0011520A
Authority
BR
Brazil
Prior art keywords
toxin
antibacterial agents
polymers used
anionic polymers
animal
Prior art date
Application number
BR0011520-7A
Other languages
English (en)
Inventor
Caroline Kurtz
Richard Fitzpatrick
Original Assignee
Geltex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharma Inc filed Critical Geltex Pharma Inc
Publication of BR0011520A publication Critical patent/BR0011520A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

"POLìMEROS ANIÈNICOS USADOS COMO LIGANTES DE TOXINAS E AGENTES ANTIBACTERIANOS". A presente invenção refere-se a um método para inibir uma toxina, em um animal, tal como um ser humano, através da administração ao animal de uma quantidade terapeuticamente efetiva de um polímero tendo uma pluralidade de grupos funcionais ácido pendente os quais são diretamente ligados a cadeia polimérica principal ou ligados a cadeia polimérica principal através de um grupo espaçador. O grupo espaçador pode Ter um comprimento em torno de o a aproximadamente 20 átomos. A toxina é, tipicamente, uma exotoxina secretada por um microrganismo patógeno, tal como uma bactéria.
BR0011520-7A 1999-05-13 2000-05-11 Polìmeros aniÈnicos usados como ligantes de toxinas e agentes antibacterianos BR0011520A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13397599P 1999-05-13 1999-05-13
US09/541,268 US6270755B1 (en) 1999-05-13 2000-04-03 Anionic polymers as toxin binders
PCT/US2000/012943 WO2000069428A2 (en) 1999-05-13 2000-05-11 Anionic polymers as toxin binders and antibacterial agents

Publications (1)

Publication Number Publication Date
BR0011520A true BR0011520A (pt) 2003-06-24

Family

ID=26831853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011520-7A BR0011520A (pt) 1999-05-13 2000-05-11 Polìmeros aniÈnicos usados como ligantes de toxinas e agentes antibacterianos

Country Status (23)

Country Link
US (2) US6270755B1 (pt)
EP (1) EP1189622B1 (pt)
JP (1) JP2002544226A (pt)
KR (1) KR100742433B1 (pt)
CN (1) CN100435806C (pt)
AT (1) ATE367818T1 (pt)
AU (1) AU768592B2 (pt)
BR (1) BR0011520A (pt)
CA (1) CA2374108A1 (pt)
DE (1) DE60035689T2 (pt)
DK (1) DK1189622T3 (pt)
ES (1) ES2288855T3 (pt)
HK (1) HK1044490A1 (pt)
HU (1) HUP0201114A3 (pt)
IL (2) IL146211A0 (pt)
MY (1) MY132695A (pt)
NO (1) NO329497B1 (pt)
NZ (1) NZ515226A (pt)
PL (1) PL197157B1 (pt)
PT (1) PT1189622E (pt)
RU (1) RU2246938C2 (pt)
TW (1) TW592704B (pt)
WO (1) WO2000069428A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270755B1 (en) * 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6805857B2 (en) * 2000-03-06 2004-10-19 Kumarpal A. Shah Method of modulating factor D, factor H and CD4 cell immune response with a polystyrene sulfonate, alginate, and saline infusion solution
CA2314494A1 (en) * 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
US6537538B2 (en) * 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
CA2492211A1 (en) * 2002-07-22 2004-01-29 Genzyme Corporation Poly(potassium and sodium styrene sulfonate), its manufacture and its uses
ATE448775T1 (de) * 2002-08-29 2009-12-15 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
US7682631B2 (en) * 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
CA2542968C (en) 2003-10-20 2013-06-04 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins
EP1802349A1 (en) * 2004-10-13 2007-07-04 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
WO2007024973A1 (en) * 2005-08-22 2007-03-01 Quick-Med Technologies, Inc. Disinfectant with quaternary ammonium polymers and copolymers
KR20080088587A (ko) * 2005-11-02 2008-10-02 슈어 인터내셔날 벤쳐스 비.브이. 세포 사멸을 위한 조성물 및 방법
TW200829286A (en) * 2006-09-06 2008-07-16 Genzyme Corp Polystyrene sulfonate polymer tablets, their preparation and use
US8809444B2 (en) * 2009-12-23 2014-08-19 Momentive Performance Materials Inc. Network copolymer crosslinked emulsions and demulsifying compositions comprising the same
JP5820112B2 (ja) * 2010-12-15 2015-11-24 積水化学工業株式会社 インフルエンザウイルス感染阻止剤、インフルエンザウイルス感染阻止塗料及びインフルエンザウイルス感染阻止製品
CN102160870B (zh) * 2011-03-18 2013-04-24 南京欧睿医药科技有限公司 聚（4-苯乙烯磺酸-共聚-马来酸）钠盐的用途及其药物组合物
CA2845091A1 (en) * 2011-09-08 2013-03-14 Safe Bt, Inc. Use of modified hollow fiber materials for removing exotoxins produced by escherichia coli from liquids, preferably from blood and plasma as well as their use for treating concomitant diseases
RU2482883C1 (ru) * 2012-03-12 2013-05-27 Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук Способ получения полимерно-композиционных волокнистых материалов с антимикробной активностью
CA2971725C (en) * 2014-12-23 2024-05-14 Ardelyx, Inc. Compositions and methods for treating hyperkalemia
KR101720053B1 (ko) 2015-04-30 2017-03-27 이현국 고주파 열처리 장치 및 고주파 열처리 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224941A (en) 1963-01-21 1965-12-21 Lilly Co Eli Resin compositions and method for controlling diarrhea
US3466365A (en) 1967-07-24 1969-09-09 White Lab Inc Antiviral compositions and method of use
GB1466702A (en) * 1973-02-09 1977-03-09 Sandoz Ltd Polymer encapsulated-activated carbon
IE44690B1 (en) 1976-02-04 1982-02-24 Rohm & Haas Pharmaceutical compositions containing polyvinylbenzenosulfonic acids
US4395392A (en) 1980-06-24 1983-07-26 Adria Laboratories Inc. Method for treating kidney stones
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
US5171738A (en) 1982-10-04 1992-12-15 Toray Industries, Inc. Method of treating malignant tumors
US5435821A (en) 1985-12-12 1995-07-25 Exxon Research & Engineering Co. Controlled release vegetation enhancement agents coated with sulfonated polymers, method of production and prcesses of use
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JPS6422551A (en) * 1987-07-16 1989-01-25 Dainippon Ink & Chemicals Composite film for lid
JPH0219319A (ja) 1988-05-26 1990-01-23 Duphar Internatl Res Bv ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物
JPH02176351A (ja) 1988-12-27 1990-07-09 Matsushita Electric Ind Co Ltd 給湯器
US5149523A (en) 1989-06-20 1992-09-22 Aktiebolaget Hassle Polystyrenesulfonate-drug complex and solid dosage forms thereof
US5093130A (en) 1989-09-26 1992-03-03 Plant Genetics Powder coated hydrogel capsules
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
FR2669535A1 (fr) * 1990-11-26 1992-05-29 Medgenix Group Sa Utilisation a titre de medicament de macromolecules polysulfonees.
ATE162081T1 (de) * 1991-09-17 1998-01-15 Alcon Lab Inc Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
US5424063A (en) 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
US5277820A (en) 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5380522A (en) * 1992-08-11 1995-01-10 Day; Charles E. Method for treatment of irritable bowel syndrome
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5614559A (en) 1993-11-23 1997-03-25 Procept Inc. Compound for inhibiting HIV infectivity
US5484773A (en) 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
EP0751765B1 (en) 1994-03-11 2003-05-07 Pharmacopeia, Inc. Sulfonamide derivatives and their use
JPH10505358A (ja) 1994-09-06 1998-05-26 ギャラゲン・インコーポレイテッド クロストリジウム・ディフィシル関連疾患の治療処置
EP0800862B1 (en) 1994-12-26 2002-02-27 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for endotoxin, tumor necrosis factor-alpha or interleukins, method for removal via adsorption, and adsorber
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
DE19549420A1 (de) 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
AUPN327695A0 (en) * 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
US5700458A (en) * 1996-09-20 1997-12-23 Geltex Pharmaceuticals Inc. Acid-functionalized saccharides as polyvalent anti-infectives
US5800803A (en) 1997-02-10 1998-09-01 Colgate-Palmolive Company Oral composition exhibiting enhanced uptake by dental tissue of noncationic antibacterial agents
US6007803A (en) * 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
US6060235A (en) 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
WO1999020285A1 (fr) 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Preparations de gels contenant un polystyrenesulfonate
US6270755B1 (en) * 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders

Also Published As

Publication number Publication date
IL146211A0 (en) 2002-07-25
CN1358097A (zh) 2002-07-10
KR100742433B1 (ko) 2007-07-24
TW592704B (en) 2004-06-21
MY132695A (en) 2007-10-31
US20010041171A1 (en) 2001-11-15
NO20015524D0 (no) 2001-11-12
DE60035689D1 (de) 2007-09-06
AU4840900A (en) 2000-12-05
IL146211A (en) 2007-06-03
NO20015524L (no) 2002-01-11
ES2288855T3 (es) 2008-02-01
DK1189622T3 (da) 2007-11-05
HUP0201114A3 (en) 2003-05-28
NO329497B1 (no) 2010-11-01
RU2246938C2 (ru) 2005-02-27
HK1044490A1 (zh) 2002-10-25
DE60035689T2 (de) 2008-04-30
US6270755B1 (en) 2001-08-07
PL352411A1 (en) 2003-08-25
HUP0201114A2 (en) 2002-09-28
AU768592B2 (en) 2003-12-18
EP1189622A2 (en) 2002-03-27
PT1189622E (pt) 2007-10-08
CN100435806C (zh) 2008-11-26
PL197157B1 (pl) 2008-03-31
CA2374108A1 (en) 2000-11-23
KR20020005032A (ko) 2002-01-16
WO2000069428A2 (en) 2000-11-23
US6419914B2 (en) 2002-07-16
NZ515226A (en) 2003-09-26
ATE367818T1 (de) 2007-08-15
EP1189622B1 (en) 2007-07-25
WO2000069428A3 (en) 2002-01-24
JP2002544226A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
BR0011520A (pt) Polìmeros aniÈnicos usados como ligantes de toxinas e agentes antibacterianos
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
NO982703L (no) Lineµre blokkpolymerer som omfatter urea- og uretangrupper, fremgangsmÕte til fremstilling av lineµre blokkpolymerer og anvendelse av blokkpolymerene som implantater
PT101300A (pt) Composicao oral antiplaca antibacteriana, contendo um agente potenciador da accao antibacteriana a base de um polimero de ligacao cruzada sintetico, e metodo para promover a higiene oral utilizando a referida composicao
DE69934010D1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
HRP20060275A2 (en) 6-0-supstituted ketolides having antibacterial activity
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
MX9205937A (es) Sistema de penetracion incrementada de la piel para surtido topico mejorado de farmacos
BR9508031A (pt) Composto antiviral composição farmacéutica ou veterinária e processo para o tratamento antiviral profilático ou terapéuitco de um humano ou animal náo humano e uso do composto
BR0206734A (pt) Polìmeros de ioneno e seu uso como agentes antimicrobianos
BR9706550A (pt) Uso polímeros de poli(ácido 2-acrilamido-2-metilpropanosulfônico) composição cosmética ou dermatológica e processo para tratamento cosmético n o terapêutico da pele
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
ES2159733T3 (es) Compuestos de dialquiltiacumicina.
WO2000040592A8 (en) Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
EP1800687A3 (en) Anionic polymers as toxin binders and antibacterial agents
DE59410133D1 (de) Orale arzneiform enthaltend colestipol als träger mit sauren wirkstoffen und verfahren zu ihrer herstellung
MX9304266A (es) Quinolinas y naftiridinas de 3-carboxaldehido sustituidas.
DE69935662D1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
AR026446A1 (es) Polimeros anionicos como ligantes de toxinas y agentes antibacterianos
DE69618813T2 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
CO4940459A1 (es) Composicion para el tratamiento de trastornos gastrointesti- nales y metodo para su fabricacion
BR9809405A (pt) Proteinase de streptococcus pneumoniae que degrada complemento humano c3
BR9611759A (pt) Processo para o tratamento ou prevenção de mucosite oral em um animal, e, composição para administração oral tópica de um peptìdeo antimicrobiano

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

Free format text: TRANSFERIDO POR FUSAO DE: GELTEX PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.